Analysts expect that Avalo Therapeutics Inc (NASDAQ:AVTX) will report earnings of ($0.16) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Avalo Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.15) and the lowest estimate coming in at ($0.17). The company is expected to report its next earnings report on Monday, March 14th.
According to Zacks, analysts expect that Avalo Therapeutics will report full year earnings of ($0.84) per share for the current fiscal year, with EPS estimates ranging from ($0.85) to ($0.82). For the next fiscal year, analysts forecast that the company will report earnings of ($0.65) per share, with EPS estimates ranging from ($0.73) to ($0.60). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that cover Avalo Therapeutics.
Avalo Therapeutics (NASDAQ:AVTX) last posted its quarterly earnings results on Tuesday, November 9th. The company reported ($0.17) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.01. Avalo Therapeutics had a negative net margin of 1,211.01% and a negative return on equity of 272.08%.
NASDAQ:AVTX opened at $2.09 on Tuesday. The company has a quick ratio of 4.04, a current ratio of 4.04 and a debt-to-equity ratio of 0.81. The business has a 50-day simple moving average of $2.26. Avalo Therapeutics has a 1-year low of $2.03 and a 1-year high of $4.50.
Several hedge funds and other institutional investors have recently bought and sold shares of AVTX. Point72 Asset Management L.P. bought a new position in shares of Avalo Therapeutics during the 3rd quarter worth approximately $13,099,000. BlackRock Inc. bought a new position in shares of Avalo Therapeutics during the 3rd quarter worth approximately $8,102,000. Integral Health Asset Management LLC bought a new position in shares of Avalo Therapeutics during the 3rd quarter worth approximately $3,543,000. Opaleye Management Inc. bought a new position in shares of Avalo Therapeutics during the 3rd quarter worth approximately $3,181,000. Finally, Geode Capital Management LLC bought a new position in shares of Avalo Therapeutics during the 3rd quarter worth approximately $2,708,000. Hedge funds and other institutional investors own 74.07% of the company’s stock.
About Avalo Therapeutics
Avalo Therapeutics, Inc is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation.
Featured Article: Understanding Average Daily Trade Volume
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.